Clinical Trial Detail

NCT ID NCT03132675
Title pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment (PISCES)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoSec Medical Incorporated
Indications

melanoma

Therapies

IL-12 gene + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.